公开(公告)号：US20130052177A1

公开(公告)日：2013-02-28

申请号：US13577090

申请日：2011-02-04

Applicant: Paul Schimmel ,  Xiang-Lei Yang ,  Bonnie Slike ,  Xiaoling Xu ,  Min Guo

Inventor： Paul Schimmel ,  Xiang-Lei Yang ,  Bonnie Slike ,  Xiaoling Xu ,  Min Guo

IPC: A61K38/45 ,  A61P29/00

CPC classification number: C12N9/93 ,  A61K38/45 ,  C07K16/1045 ,  C07K16/40 ,  C12Y601/01 ,  C12Y601/01001 ,  C12Y601/01002 ,  C12Y601/01006 ,  Y02A50/473

Abstract: Isolated monomelic aminoacyl-tRNA synthetase polypeptides and polynucleotides having non-canonical biological activities are provided, as well as compositions and methods related thereto.

Abstract translation: 提供了分离的单体氨酰-tRNA合成酶多肽和具有非规范生物活性的多核苷酸，以及与其相关的组合物和方法。

公开(公告)号：US07476651B2

公开(公告)日：2009-01-13

申请号：US11903030

申请日：2007-09-20

Applicant: Paul Schimmel ,  Keisuke Wakasugi ,  Martin Friedlander

Inventor： Paul Schimmel ,  Keisuke Wakasugi ,  Martin Friedlander

IPC: A61K38/00 ,  C12N9/10

CPC classification number: C12N9/93 ,  A61K38/00 ,  C07H21/04 ,  C07K14/515 ,  C07K14/521 ,  C12Y601/01002 ,  Y10S435/975

Abstract: The invention provides a method for inhibiting ocular neovascularization in a patient. The method comprises administering to a patient an ocular neovascularization inhibiting amount of a water-soluble polypeptide selected from the group consisting of SEQ ID NO: 12, SEQ ID NO: 7, and an ocular neovascularization inhibiting fragment thereof, which includes at least one of amino acid residue signature sequences HVGH (SEQ ID NO:10) and KMSAS (SEQ ID NO:11). A method for assaying the angiogenesis inhibiting activity of a composition is also provided.

Abstract translation: 本发明提供一种抑制患者眼新生血管形成的方法。 该方法包括向患者施用眼新生血管形成抑制量的选自SEQ ID NO：12，SEQ ID NO：7的水溶性多肽和其新生血管形成抑制片段，其包括至少一种 氨基酸残基特征序列HVGH（SEQ ID NO：10）和KMSAS（SEQ ID NO：11）。 还提供了用于测定组合物的血管发生抑制活性的方法。

公开(公告)号：US20230313129A1

公开(公告)日：2023-10-05

申请号：US18040933

申请日：2021-08-06

Applicant: BrickBio, Inc.

Inventor： James Sebastian Italia ,  Zhi Li

IPC: C12N5/07 ,  C12N9/00 ,  C12N15/63

CPC classification number: C12N5/06 ,  C12N9/93 ,  C12Y601/01002 ,  C12Y601/01004 ,  C12N15/63

Abstract: The invention relates generally to engineered tRNAs, engineered aminoacyl-tRNA synthetases, unnatural amino acids, and cells comprising the same, and their use in the incorporation of unnatural amino acids into proteins.

公开(公告)号：US20180064790A1

公开(公告)日：2018-03-08

申请号：US15686557

申请日：2017-08-25

Applicant: MEDICINAL BIOCONVERGENCE RESEARCH CENTER ,  DAEJEON UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION

Inventor： Sunghoon KIM ,  Mi Rim JIN ,  Young Ha AHN

IPC: A61K38/53 ,  A23L33/10 ,  A23L33/00

CPC classification number: A61K38/53 ,  A23L33/10 ,  A23L33/40 ,  A23V2002/00 ,  A61P29/00 ,  A61P31/00 ,  A61P31/04 ,  A61P31/10 ,  A61P31/12 ,  C12N9/00 ,  C12Y601/01002

Abstract: The present invention relates to a composition for treatment or prevention of infectious inflammatory diseases comprising tryptophanyl-tRNA synthetase as an active ingredient, and a composition for immune enhancement. More specifically, the present invention relates to a pharmaceutical composition for treatment or prevention of infectious inflammatory diseasess comprising tryptophanyl-tRNA synthetase as an active ingredient, a food composition for preventing or improving, a veterinary composition for preventing or treating, and a composition for immune enhancement comprising a tryptophanyl-tRNA synthetase as an active ingredient, respectively.The composition of the present invention can be effectively used for preventing or treating diseases of humans and animals caused by infection from bacteria, viruses or fungi and the like by inhibiting infections such as bacterial, viral, and fungal infections at an early stage particularly through activating innate immune response.

公开(公告)号：US08796237B2

公开(公告)日：2014-08-05

申请号：US13229866

申请日：2011-09-12

Applicant: Paul Schimmel ,  Keisuke Wakasugi ,  Martin Friedlander

Inventor： Paul Schimmel ,  Keisuke Wakasugi ,  Martin Friedlander

IPC: C07H21/04 ,  C07K14/515

CPC classification number: C12N9/93 ,  A61K38/00 ,  C07H21/04 ,  C07K14/515 ,  C07K14/521 ,  C12Y601/01002 ,  Y10S435/975

Abstract: The invention provides an isolated nucleic acid encoding a polypeptide capable of inhibiting angiogenesis or neovascularization, wherein the nucleic acid comprises a first polynucleotide sequence comprising a coding sequence at least 95 percent identical to a sequence selected from the group consisting of a polynucleotide SEQ ID NO:6, a polynucleotide that encodes a polypeptide of SEQ ID NO:12, and a polynucleotide that encodes a fragment of the polypeptide of SEQ ID NO:12; and wherein the nucleic acid does not encode for the amino acid sequence of amino acids 71-93 of SEQ ID NO:1. Pharmaceutical compositions, vectors, and methods for inhibiting neovascularization or angiogenesis comprising or utilizing the nucleic acids also are provided.

Abstract translation: 本发明提供了编码能够抑制血管生成或新生血管形成的多肽的分离的核酸，其中所述核酸包含第一多核苷酸序列，所述第一多核苷酸序列包含与选自多核苷酸SEQ ID NO： 6，编码SEQ ID NO：12的多肽的多核苷酸和编码SEQ ID NO：12的多肽的片段的多核苷酸; 并且其中所述核酸不编码SEQ ID NO：1的氨基酸71-93的氨基酸序列。 还提供了用于抑制新生血管形成或血管发生的药物组合物，载体和方法，其包含或利用核酸。

公开(公告)号：US08017593B2

公开(公告)日：2011-09-13

申请号：US12319822

申请日：2009-01-13

Applicant: Paul Schimmel ,  Keisuke Wakasugi ,  Martin Friedlander

Inventor： Paul Schimmel ,  Keisuke Wakasugi ,  Martin Friedlander

IPC: A61K48/00

CPC classification number: C12N9/93 ,  A61K38/00 ,  C07H21/04 ,  C07K14/515 ,  C07K14/521 ,  C12Y601/01002 ,  Y10S435/975

Abstract: The invention provides a method for inhibiting ocular neovascularization in a patient. The method comprises administering to a patient an ocular neovascularization inhibiting amount of a water-soluble polypeptide selected from the group consisting of SEQ ID NO: 12, SEQ ID NO: 7, and an ocular neovascularization inhibiting fragment thereof, which includes at least one of amino acid residue signature sequences HVGH (SEQ ID NO:10) and KMSAS (SEQ ID NO:11). A method for assaying the angiogenesis inhibiting activity of a composition is also provided.

Abstract translation: 本发明提供一种抑制患者眼新生血管形成的方法。 该方法包括向患者施用眼新生血管形成抑制量的选自SEQ ID NO：12，SEQ ID NO：7的水溶性多肽和其新生血管形成抑制片段，其包括至少一种 氨基酸残基特征序列HVGH（SEQ ID NO：10）和KMSAS（SEQ ID NO：11）。 还提供了用于测定组合物的血管发生抑制活性的方法。

公开(公告)号：US20090275643A1

公开(公告)日：2009-11-05

申请号：US12319822

申请日：2009-01-13

Applicant: Paul Schimmel ,  Keisuke Wakasugi ,  Martin Friedlander

Inventor： Paul Schimmel ,  Keisuke Wakasugi ,  Martin Friedlander

IPC: A61K31/711 ,  G01N33/483

CPC classification number: C12N9/93 ,  A61K38/00 ,  C07H21/04 ,  C07K14/515 ,  C07K14/521 ,  C12Y601/01002 ,  Y10S435/975

Abstract: The invention provides a method for inhibiting ocular neovascularization in a patient. The method comprises administering to a patient an ocular neovascularization inhibiting amount of a water-soluble polypeptide selected from the group consisting of SEQ ID NO: 12, SEQ ID NO: 7, and an ocular neovascularization inhibiting fragment thereof, which includes at least one of amino acid residue signature sequences HVGH (SEQ ID NO:10) and KMSAS (SEQ ID NO:11). A method for assaying the angiogenesis inhibiting activity of a composition is also provided

Abstract translation: 本发明提供一种抑制患者眼新生血管形成的方法。 该方法包括向患者施用眼新生血管形成抑制量的选自SEQ ID NO：12，SEQ ID NO：7的水溶性多肽和其新生血管形成抑制片段，其包括至少一种 氨基酸残基特征序列HVGH（SEQ ID NO：10）和KMSAS（SEQ ID NO：11）。 还提供了用于测定组合物的血管发生抑制活性的方法

公开(公告)号：US07273844B2

公开(公告)日：2007-09-25

申请号：US10982014

申请日：2004-11-04

Applicant: Paul Schimmel ,  Keisuke Wakasugi ,  Martin Friedlander

Inventor： Paul Schimmel ,  Keisuke Wakasugi ,  Martin Friedlander

IPC: A61K38/00 ,  A61K38/45 ,  G01N33/53

CPC classification number: C12N9/93 ,  A61K38/00 ,  C07H21/04 ,  C07K14/515 ,  C07K14/521 ,  C12Y601/01002 ,  Y10S435/975

Abstract: An isolated, water-soluble polypeptide fragment of human tryptophanyl-tRNA synthetase is useful for the inhibition of angiogenesis. The polypeptide has the amino acid residue sequence shown in SEQ ID NO: 7, SEQ ID NO: 12, or an angiogenesis inhibiting fragment thereof, the fragment including at least one of amino acid residue signature sequences HVGH (SEQ ID NO:10) and KMSAS (SEQ ID NO:11). Methods of using the polypeptide to inhibit angiogenesis are also provided.

Abstract translation: 人色氨酰-tRNA合成酶的分离的水溶性多肽片段可用于抑制血管发生。 该多肽具有SEQ ID NO：7，SEQ ID NO：12所示的氨基酸残基或其血管生成抑制片段，该片段包括氨基酸残基特征序列HVGH（SEQ ID NO：10）和 KMSAS（SEQ ID NO：11）。 还提供了使用该多肽抑制血管生成的方法。

公开(公告)号：US20050197298A1

公开(公告)日：2005-09-08

申请号：US10982014

申请日：2004-11-04

Applicant: Paul Schimmel ,  Keisuke Wakasugi ,  Martin Friedlander

Inventor： Paul Schimmel ,  Keisuke Wakasugi ,  Martin Friedlander

IPC: A61K38/00 ,  C07H21/04 ,  C07K14/515 ,  C07K14/52 ,  C12N9/00 ,  A61K38/08 ,  A61K48/00 ,  C12N9/22 ,  C12Q1/68

CPC classification number: C12N9/93 ,  A61K38/00 ,  C07H21/04 ,  C07K14/515 ,  C07K14/521 ,  C12Y601/01002 ,  Y10S435/975

Abstract: An isolated, water-soluble polypeptide fragment of human tryptophanyl-tRNA synthetase is useful for the inhibition of angiogenesis. The polypeptide has the amino acid residue sequence shown in SEQ ID NO: 7, SEQ ID NO: 12, or an angiogenesis inhibiting fragment thereof, the fragment including at least one of amino acid residue signature sequences HVGH (SEQ ID NO:10) and KMSAS (SEQ ID NO:11). Methods of using the polypeptide to inhibit angiogenesis are also provided.

Abstract translation: 人色氨酰-tRNA合成酶的分离的水溶性多肽片段可用于抑制血管发生。 该多肽具有SEQ ID NO：7，SEQ ID NO：12所示的氨基酸残基或其血管生成抑制片段，该片段包括氨基酸残基特征序列HVGH（SEQ ID NO：10）和 KMSAS（SEQ ID NO：11）。 还提供了使用该多肽抑制血管生成的方法。

公开(公告)号：US20180275127A1

公开(公告)日：2018-09-27

申请号：US15908568

申请日：2018-02-28

Applicant: JW BIOSCIENCE

Inventor： Sunghoon KIM ,  Mi Rim JIN ,  Young Ha AHN

IPC: G01N33/573 ,  C07K16/40 ,  C12Q1/6813 ,  C12Q1/689 ,  C12Q1/70

CPC classification number: G01N33/573 ,  C07K16/40 ,  C12Q1/68 ,  C12Q1/6813 ,  C12Q1/6883 ,  C12Q1/689 ,  C12Q1/701 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/158 ,  C12Y601/01002 ,  G01N2333/9015 ,  G01N2800/26 ,  G01N2800/56 ,  Y02A50/59

Abstract: The present invention relates to a composition for diagnosing infectious diseases by using a tryptophanyl-tRNA synthase (WRS) and a method for detecting a diagnostic marker and, more specifically, to: a composition for diagnosing infectious diseases, containing a preparation measuring the WRS protein or mRNA expression level; a diagnostic kit; a method for detecting the WRS for providing information required for the diagnosis of infectious diseases, and a method for determining the infectious disease mortality risk by using the WRS. According to the present invention, the WRS is increased only in infection-induced infectious diseases, differentiating non-infectious diseases therefrom, and is rapidly increased in the early stage of infection. In addition, the level of the WRS is closely correlated with the severity and prognosis of diseases or complications induced by infection. Therefore, the WRS can be used as a marker for more rapid and accurate diagnosis, in comparison to a conventional marker for infectious diseases or complications thereof.